Growth Metrics

Pfizer (PFE) Retained Earnings (2016 - 2026)

Pfizer has reported Retained Earnings over the past 18 years, most recently at -$7.2 billion for Q1 2026.

  • Quarterly Retained Earnings rose 16.06% to -$7.2 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$7.2 billion through Mar 2026, up 16.06% year-over-year, with the annual reading at $114.6 billion for FY2025, 1561.49% up from the prior year.
  • Retained Earnings was -$7.2 billion for Q1 2026 at Pfizer, down from $114.6 billion in the prior quarter.
  • Over five years, Retained Earnings peaked at $126.4 billion in Q4 2023 and troughed at -$8.6 billion in Q1 2025.
  • The 5-year median for Retained Earnings is -$7.8 billion (2024), against an average of $29.4 billion.
  • Year-over-year, Retained Earnings crashed 108.04% in 2022 and then soared 1636.91% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$8.3 billion in 2022, then surged by 1525.25% to $118.4 billion in 2023, then plummeted by 106.63% to -$7.8 billion in 2024, then soared by 1561.49% to $114.6 billion in 2025, then plummeted by 106.28% to -$7.2 billion in 2026.
  • Per Business Quant, the three most recent readings for PFE's Retained Earnings are -$7.2 billion (Q1 2026), $114.6 billion (Q4 2025), and -$8.1 billion (Q3 2025).